NCT03235583

MOTIONPODTM Validation in Free-living Conditio

Completed NA Last updated 4 August 2017

What this trial tests

NA trial testing MOTIONPODTM device validation in Obese in 128 participants. Completed in 11 October 2013.

Timeline

2 April 2012

Primary endpoint
11 October 2013

11 October 2013

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	128
Start date	2 April 2012
Primary completion	11 October 2013
Estimated completion	11 October 2013
Sites	1 location across France

Drugs / interventions tested

• MOTIONPODTM device validation

Conditions studied

• Obese — all drugs for Obese →
• Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Adults 18 to 75, any sex, with Obese or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators propose to assess the validity in measuring physical activity (PA) of a new PA monitor system the MOTIONPODTM, that coupled a hip-worn multi-sensor device (associating a tri-axial accelerometer, a magnetometer and a gyroscope) with an automatic activity/posture recognition algorithm and an activity-specific multilinear prediction model. The MOTIONPODTM performances in predicting mean daily PA energy expenditure (PAEE) will be calculated against the reference PAEE gold standard measure, using the doubly labeled water method (DLW). The MOTIONPODTM performances in predicting PAEE and PA patterns will be compared to those of two existing activity or movement monitors: the triaxial accelerometer ActigraphGT3X+TM and a device combining cardiofrequencemetry with accelerometry, the ActiheartTM. This latter has demonstrated fair performances but at the cost of a calibration of the heart-rate/EE relationship that limits its use in large population samples. Briefly, this open study will include 120 subjects, aged 18 to 75 years of both gender and with broad range of body mass index and physical activity level. The subjects will carry a MOTIONPODTM, an ActigraphGT3X+TM, an ActiheartTM and a GPS for a total of 14 days in everyday life conditions and complete a physical activity diary. In half of the subjects, PA will be evaluated on a period of 14 days, with standard PAEE measured by DLW. The other 60 subjects will be studied twice, one month apart, to test the reproducibility of the measures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.